FUSN - Fusion Pharmaceuticals Inc.

QQQ $ 473.83 $ -2.14 (-0.45 %)

DIA $ 417.12 $ -0.12 (-0.03 %)

SPY $ 563.14 $ 0.30 (0.05 %)

TLT $ 100.82 $ -0.51 (-0.5 %)

GLD $ 237.35 $ -1.32 (-0.55 %)

Previous Close

$ 21.55

Open

Bid

-- x --

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 2.31 - $ 21.60

Volume

6,089,181

Average Volume

Market Cap

1.81B

Beta (5Y Monthly)

$ 0.51

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Fusion Pharmaceuticals Obtains Final Court...
05/31/2024 20:08:50

Fusion Pharmaceuticals Shareholders Approv...
05/29/2024 20:10:23

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjuga...

Fusion Pharmaceuticals Announces First Pat...
05/09/2024 21:28:59

AlphaBreak is a Phase 2/3 registrational program for FPI-2265 in patients with metastatic castration-resistant prostate cancerH...

Fusion Pharmaceuticals Q1 2024 GAAP EPS $(...
05/07/2024 11:08:51

Fusion Pharmaceuticals (NASDAQ:FUSN) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate...

top-4-health-care-stocks-that-may-plunge-this-month

Top 4 Health Care Stocks That May Plunge T...
04/26/2024 12:09:27

AstraZeneca, Through A Subsidiary, Will Ac...
04/25/2024 21:12:53

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjuca...

TD Cowen Downgrades Fusion Pharmaceuticals...
04/16/2024 11:52:46

TD Cowen analyst Tara Bancroft downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Buy to Hold.

astrazeneca-hikes-annual-dividend-by-7-just-before-vote-on-its-ceos-pay-package-boost

AstraZeneca Hikes Annual Dividend By 7% Ju...
04/11/2024 13:04:00

AstraZeneca boosts its 2024 dividend to $3.10/share, reflecting confidence in performance. Shareholder concerns addressed as CE...

Fusion Pharmaceuticals Hightlights Present...
04/09/2024 20:44:16

astrazeneca-ceo-highlights-decade-long-sales-goal-of-45b-along-with-investor-doubts-as-it-lags-in-weight-loss-race

AstraZeneca CEO Highlights Decade-Long Sal...
04/02/2024 18:54:01

AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. ...

RBC Capital Reiterates Sector Perform on F...
03/21/2024 15:00:09

RBC Capital analyst Gregory Renza reiterates Fusion Pharmaceuticals (NASDAQ:FUSN) with a Sector Perform and maintains $21 pr...

Wedbush Reiterates Neutral on Fusion Pharm...
03/21/2024 13:36:22

Wedbush analyst David Nierengarten reiterates Fusion Pharmaceuticals (NASDAQ:FUSN) with a Neutral and maintains $24 price ta...

Recap: Fusion Pharmaceuticals Q4 Earnings
03/20/2024 21:30:22

Fusion Pharmaceuticals Q4 2023 GAAP EPS $(...
03/20/2024 20:22:26

Fusion Pharmaceuticals (NASDAQ:FUSN) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate...

Raymond James Downgrades Fusion Pharmaceut...
03/20/2024 14:04:20

Raymond James analyst Rahul Sarugaser downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Strong Buy to Market Perform.

B. Riley Securities Downgrades Fusion Phar...
03/20/2024 14:02:29

B. Riley Securities analyst Yuan Zhi downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Buy to Neutral and raises the pric...

Truist Securities Downgrades Fusion Pharma...
03/20/2024 12:46:41

Truist Securities analyst Nicole Germino downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Buy to Hold and raises the pri...

Unveiling 11 Analyst Insights On Fusion Ph...
03/20/2024 12:01:19

RBC Capital Downgrades Fusion Pharmaceutic...
03/20/2024 11:26:31

RBC Capital analyst Gregory Renza downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Outperform to Sector Perform and rais...

JonesTrading Downgrades Fusion Pharmaceuti...
03/20/2024 08:45:17

JonesTrading analyst Justin Walsh downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Buy to Hold.